Interaction with PI3-kinase contributes to the cytotoxic activity of Apoptin

被引:39
|
作者
Maddika, S. [2 ,3 ]
Wiechec, E. [2 ,4 ]
Ande, S. R. [2 ,3 ]
Poon, I. K. [5 ]
Fischer, U. [6 ]
Wesselborg, S. [7 ]
Jans, D. A. [5 ]
Schulze-Osthoff, K. [6 ]
Los, M. [1 ,2 ,3 ,8 ,9 ]
机构
[1] BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada
[2] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada
[4] Univ Aarhus, Inst Human Genet, Aarhus, Denmark
[5] Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia
[6] Univ Dusseldorf, Inst Mol Med, Dusseldorf, Germany
[7] Univ Tubingen, Dept Internal Med 1, Tubingen, Germany
[8] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB, Canada
[9] Univ Manitoba, Dept Human Anat & Cell Biol, Winnipeg, MB, Canada
关键词
anticancer drugs; apoptin; apoptosis; PI3-kinase;
D O I
10.1038/sj.onc.1210958
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apoptin, a small protein from the chicken anemia virus, has attracted attention because of its specificity in killing tumor cells. Localization of apoptin in the nucleus of tumor cells has been shown to be vital for proapoptotic activity, however, targeted expression of apoptin in the nucleus of normal cells does not harm the cells, indicating that nuclear localization of apoptin is insufficient for its cytotoxicity. Here, we demonstrate for the first time that apoptin interacts with the SH3 domain of p85, the regulatory subunit of phosphoinositide 3-kinase (PI3-K), through its proline-rich region. Apoptin derivatives devoid of this proline-rich region do not interact with p85, are unable to activate PI3-K, and show impaired apoptosis induction. Moreover, apoptin mutants containing the proline-rich domain are sufficient to elevate PI3-K activity and to induce apoptosis in cancer cells. Downregulation of p85 leads to nuclear exclusion of apoptin and impairs cell death induction, indicating that interaction with the p85 PI3-K subunit essentially contributes to the cytotoxic activity of apoptin.
引用
收藏
页码:3060 / 3065
页数:6
相关论文
共 50 条
  • [11] PI3-kinase signaling contributes to orientation in shallow gradients and enhances speed in steep chemoattractant gradients
    Bosgraaf, Leonard
    Keizer-Gunnink, Ineke
    van Haastert, Peter J. M.
    JOURNAL OF CELL SCIENCE, 2008, 121 (21) : 3589 - 3597
  • [12] Exocytic vesicle formation requires interaction between a PI3-kinase and PI-transfer protein.
    Jones, SM
    Bankaitis, VA
    Howell, KE
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 2566 - 2566
  • [13] Role of PI3-kinase signalling in uterine carcinosarcoma
    Doneza, J.
    Arend, R.
    Chen, X.
    Galatioto, J.
    Kitajewski, J.
    Li, B.
    Herzog, T.
    Wright, J.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S152 - S152
  • [14] Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity
    Isenovic, E
    Muniyappa, R
    Milivojevic, N
    Rao, Y
    Sowers, JR
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 285 (04) : 954 - 958
  • [15] PI3-Kinase Controls Smooth Muscle Contraction Via Regulation Of MLCP Activity
    Sakai, Hiroyasu
    Ikebe, Mitsuo
    BIOPHYSICAL JOURNAL, 2009, 96 (03) : 226A - 226A
  • [16] Susi, a negative regulator of Drosophila PI3-kinase
    Wittwer, F
    Jaquenoud, M
    Brogiolo, W
    Zarske, M
    Wüstemann, P
    Fernandez, R
    Stocker, H
    Wymann, MP
    Hafen, E
    DEVELOPMENTAL CELL, 2005, 8 (06) : 817 - 827
  • [17] PI3-kinase inhibition: a target for drug development?
    Stein, RC
    Waterfield, MD
    MOLECULAR MEDICINE TODAY, 2000, 6 (09): : 347 - 357
  • [18] PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
    Chang, Julie E.
    Kahl, Brad S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (01) : 33 - 43
  • [19] Small Molecule Inhibitors of the PI3-Kinase Family
    Knight, Zachary A.
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 2, 2011, 347 : 263 - 278
  • [20] PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia
    Julie E. Chang
    Brad S. Kahl
    Current Hematologic Malignancy Reports, 2014, 9 : 33 - 43